Macupatide for obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 10 Oct 2025: Trial registered, NCT07215559
  2. 16 Oct 2025: Trial started, NCT07215559
  3. 15 May 2026: Trial registered, NCT07589608
  4. 15 May 2026: Trial started, NCT07589608

The trials

NCT07215559: A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

State
Under way
Phase
Phase 2
People
200 planned
Started
16 Oct 2025
Primary completion
Mar 2027
Arms
Macupatide (Macupatide + Eloralintide Placebo)
Results
None posted
  1. 10 Oct 2025: Trial registered
  2. 16 Oct 2025: Trial started

NCT07589608: A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

State
Under way
Phase
Phase 2
People
400 planned
Started
15 May 2026
Primary completion
Sep 2027
Arms
Macupatide Dose 1
Results
None posted
  1. 15 May 2026: Trial registered
  2. 15 May 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.